Date:	2023.09.30			
Your Name:	Wen Zhe	xu		
Manuscript Title:	Residual Tumor Descri	ptors Proposed by	the International Association	on for the Study of Lung
Cancer may not be ap	plicable to Stage I and GO	3O-featured NSCLC		_
Manuscript number (if known):	TLCR-23-497		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	-	Time frame: Since the initial	planning of the work
1	All support for the present	X_None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X_None	
4	Canaultina food	V Nege	
4	Consulting fees	X_None	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
_			
7	Support for attending meetings and/or travel	X_None	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		

No conflict of interest.		

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023.09.29			
Your Name:	Fu Fang	qiu		
Manuscript Title:	Residual Tumor Descrip	tors Proposed by the	e International Association for the Study of Lu	ng
Cancer may not be ap	plicable to Stage I and GG(O-featured NSCLC		
Manuscript number (i	f known):	TLCR-23-497		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	X_None	
4	Consulting fees	X_None	

5	Payment or honoraria for	X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
_			
7	Support for attending meetings and/or travel	X_None	
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X_None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		

No conflict of interest.		

Please place an "X" next to the following statement to indicate your agreement:

	te:2			
	ur Name:			
			posed by the International Association for the Study of	Lung
Ca	ncer may not be applicable t	to Stage I and GGO-feature	ed NSCLC	
Ma	nuscript number (if known)): TLCR	-23-497	
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to		ension, you should declare	defined broadly. For example, if your manuscript pertal all relationships with manufacturers of antihypertensions the manuscript.	
	item #1 below, report all su e time frame for disclosure i	•	ed in this manuscript without time limit. For all other it	tems,
		Name all entities with	Specifications/Comments	
			Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	l planning of the work	
1	All support for the present	_XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
			+	
			-	
		Time frame: past	36 months	
2	Grants or contracts from	_XNone		
	any entity (if not indicated in item #1 above).			

3

4

Royalties or licenses

Consulting fees

X__None

X__None

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending	_XNone	
	meetings and/or travel		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No conflict of interest.			

Please place an "X" next to the following statement to indicate your agreement:

Da	te:2	2023.10.03		
Yo	ur Name:	Gao ZhenDong		
Ma	anuscript Title: Residu	ual Tumor Descriptors Pro	posed by the International Association for the Study of	Lung
Ca	ncer may not be applicable	to Stage I and GGO-featui	red NSCLC	
Ma	anuscript number (if known)): TLCF	R-23-497	
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmen s. If you are in doubt about whether to list a lo so.	
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypertedication, even if that medic	ension, you should declar cation is not mentioned in pport for the work report	e <u>defined broadly</u> . For example, if your manuscript pert e all relationships with manufacturers of antihypertens the manuscript. ed in this manuscript without time limit. For all other i	sive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initi	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone		
		Time frame: pas	t 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone		

3

4

Royalties or licenses

Consulting fees

X__None

_X__None

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending	_XNone	
	meetings and/or travel		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No conflict of interest.			

Please place an "X" next to the following statement to indicate your agreement:

		ICIVIJE DISC	LOSURE FORIVI	
Da	te:2	2023.10.11		
	ur Name:	Han Han		
Ma	nuscript Title: Residu	ual Tumor Descriptors Pro	posed by the International Association for the Study of	Lung
Caı	ncer may not be applicable	to Stage I and GGO-featur	red NSCLC	
Ma	nuscript number (if known)): TLCR	-23-497	
rela pai to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that ar eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmer . If you are in doubt about whether to list a o so.	
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to	•	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pert e all relationships with manufacturers of antihypertens the manuscript.	
	item #1 below, report all su e time frame for disclosure i		ed in this manuscript without time limit. For all other i	tems,
		Name all entities with	Specifications/Comments	1
		whom you have this	(e.g., if payments were made to you or to your	i
		relationship or indicate	institution)	i
		none (add rows as	,	ì
		needed)		ì
		Time frame: Since the initia	al planning of the work	ì
	All support for the present	_XNone		1
	manuscript (e.g., funding,			İ
	provision of study materials,			ì
	medical writing, article			İ
	processing charges, etc.)			

	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	
	_	_	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
42	5	V N	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No conflict of interest.			

Please place an "X" next to the following statement to indicate your agreement:

Da	te:2	2023.09.29	
Yo	ur Name:	Li Hang	
Ma	anuscript Title: Residu	ual Tumor Descriptors Pro	oposed by the International Association for the Study of Lun
Ca	ncer may not be applicable	to Stage I and GGO-featu	red NSCLC
Ma	nuscript number (if known)): TLCI	R-23-497
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" m e affected by the content necessarily indicate a bia	all relationships/activities/interests listed below that are leans any relation with for-profit or not-for-profit third to of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.
	e following questions apply inuscript only.	to the author's relations	hips/activities/interests as they relate to the current
to	• •	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.
	item #1 below, report all su e time frame for disclosure i		ted in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
	•	Time frame: Since the init	ial planning of the work
L	All support for the present	_XNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pa	st 36 months
)	Grants or contracts from	_XNone	
	any entity (if not indicated		
	in item #1 above).		
}	Royalties or licenses	_XNone	

Consulting fees

X__None

4

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending	_XNone	
	meetings and/or travel		
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No conflict of interest.			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023.10.01	
Your Name:	Ye Ting	
Manuscript Title:	_ Residual Tumor Des	riptors Proposed by the International Association for the Study of Lung
Cancer may not be app	licable to Stage I and	GGO-featured NSCLC
Manuscript number (if	known):	TLCR-23-497
	•	o disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	_X_None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	_X_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_X_None	
	testimony		
7	Support for attending meetings and/or travel	_X_None	
	G ,		
8	Patents planned, issued or	_X_None	
	pending		
9	Participation on a Data	_X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_X_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_X_None	
12	Receipt of equipment,	_X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_X_None	
	financial interests		

No conflict of interest.		

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023.10.01	
Your Name:	Hu Hong	
Manuscript Title:	Residual Tumor Descripto	ors Proposed by the International Association for the Study of Lung
Cancer may not be a	oplicable to Stage I and GGO	-featured NSCLC
Manuscript number	(if known):	TLCR-23-497
related to the conter parties whose intere	nt of your manuscript. "Relat sts may be affected by the co	close all relationships/activities/interests listed below that are ed" means any relation with for-profit or not-for-profit third ontent of the manuscript. Disclosure represents a commitment e a bias. If you are in doubt about whether to list a
relationship/activity	/interest, it is preferable tha	t you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_X_None	
4	Consulting fees	_XNone	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
42	5	V N	
12	Receipt of equipment, materials, drugs, medical	_XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No conflict of interest.		

Please place an "X" next to the following statement to indicate your agreement:

Da	te:2	2023.9.28		
Yo	ur Name:	Sun Yihua		
Ma	anuscript Title: Residu	ual Tumor Descriptors Pro	pposed by the International Association for the Study of Lui	ng
		_	red NSCLC	
Ma	nuscript number (if known)): TLCF	R-23-497	
		•	Ill relationships/activities/interests listed below that are	
	-	•	eans any relation with for-profit or not-for-profit third	
-	-		of the manuscript. Disclosure represents a commitment	
	transparency and does not i ationship/activity/interest,	•	s. If you are in doubt about whether to list a	
ıeı	ationship, activity, interest,	it is preferable that you c	io 50.	
	e following questions apply inuscript only.	to the author's relationsl	nips/activities/interests as they relate to the <u>current</u>	
to	•	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive n the manuscript.	;
	item #1 below, report all su e time frame for disclosure i	• •	ed in this manuscript without time limit. For all other item	iS,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed) Time frame: Since the initi	al planning of the work	
	All support for the present	X None	all planning of the work	
-	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		- : c	. 25	
)	Grants or contracts from	Time frame: pas	st 36 months	
_	any entity (if not indicated	_^None		
	in item #1 above).			
}	Royalties or licenses	X None		
	,			

4

Consulting fees

X_None

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_XNone	
	financial interests		

No conflict of interest.	

Please place an "X" next to the following statement to indicate your agreement:

Da	te:2	2023.10.02	
Yo	ur Name:	Li Yuan	
			oposed by the International Association for the Study of Lung
Ca	ncer may not be applicable	to Stage I and GGO-featu	red NSCLC
Ma	nuscript number (if known)): TLCI	R-23-497
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" m e affected by the content necessarily indicate a bia	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.
	e following questions apply inuscript only.	to the author's relations	hips/activities/interests as they relate to the current
to	•	ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.
	item #1 below, report all su e time frame for disclosure i	• •	ted in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	,
		needed)	
		Time frame: Since the initi	ial planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pa	st 26 months
)	Grants or contracts from	X None	st 30 months
_	any entity (if not indicated	_^NONE	+
	in item #1 above).		
,	•	V None	
5	Royalties or licenses	_XNone	

4

Consulting fees

X__None

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		

No conflict of interest.

Please place an "X" next to the following statement to indicate your agreement:

		ICMJE DISC	CLOSURE FORM	
Date	e:	_2023.10.10		
You	r Name:Zhan	g Yang		
			posed by the International Association for the Study of	Lung
Can	cer may not be applicable	e to Stage I and GGO-featu	red NSCLC	
Mar	nuscript number (if know	n): TLCF	R-23-497	
rela part to ti	ted to the content of you ties whose interests may ransparency and does no	r manuscript. "Related" m be affected by the content	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment In Jou are in doubt about whether to list a Io so.	
	following questions appl	y to the author's relationsl	nips/activities/interests as they relate to the current	
to tl	he epidemiology of hypei		e <u>defined broadly</u> . For example, if your manuscript pertage all relationships with manufacturers of antihypertensing the manuscript.	
	em #1 below, report all s time frame for disclosure		ed in this manuscript without time limit. For all other it	tems,
		Name all entities with	Specifications/Comments	
		whom you have this	-	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial _XNone	pranning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	_XNone	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
8	Patents planned, issued or	_XNone	
	pending		
9	Participation on a Data	_XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	V Nege	
13	other financial or non- financial interests	_XNone	
	illialiciai liiterests		

No conflict of intere	st.		

Please place an "X" next to the following statement to indicate your agreement:

Date:			2023.10.15
Your Name:		Haiquan	
Manuscript Title:	Residual Tumor [Descriptors Proposed by	the International Association for the Study of Lung
Cancer may not be a	pplicable to Stage I a	nd GGO-featured NSCLO	<u> </u>
Manuscript number	(if known):	TLCR-23-497_	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_XNone		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	X None		
11	Stock of Stock options	_XNone		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X None		
12		XNone		
	services			
13	Other financial or non-	X None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
	The author declares no conflicts of interest.			
1				

Please place an "X" next to the following statement to indicate your agreement: